BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 133 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2018. The put-call ratio across all filers is 0.63 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,271,000 | +19.8% | 21,635 | +15.5% | 0.01% | +33.3% |
| Q2 2022 | $2,730,000 | +9.2% | 18,737 | -11.1% | 0.01% | +20.0% |
| Q1 2022 | $2,500,000 | -22.8% | 21,081 | -10.2% | 0.01% | -16.7% |
| Q4 2021 | $3,237,000 | -18.8% | 23,488 | -18.1% | 0.01% | -14.3% |
| Q3 2021 | $3,984,000 | +414.7% | 28,683 | +259.9% | 0.01% | +600.0% |
| Q2 2021 | $774,000 | -43.5% | 7,970 | -60.2% | 0.00% | -50.0% |
| Q1 2021 | $1,369,000 | -21.0% | 20,027 | -0.9% | 0.00% | -33.3% |
| Q4 2020 | $1,733,000 | +4.6% | 20,217 | -20.7% | 0.00% | 0.0% |
| Q3 2020 | $1,657,000 | +94.0% | 25,487 | +118.1% | 0.00% | +200.0% |
| Q2 2020 | $854,000 | -4.8% | 11,685 | -55.7% | 0.00% | -50.0% |
| Q1 2020 | $897,000 | +311.5% | 26,370 | +353.5% | 0.00% | – |
| Q3 2018 | $218,000 | – | 5,815 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
| Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
| ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
| Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
| Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
| Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |